ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell (Nasdaq: ICCC) expects to report unaudited financial results for the quarter ended June 30, 2026 after market close on August 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) expects to report unaudited financial results for the quarter ended June 30, 2026 after market close on August 13, 2026. The Company will host a conference call and webcast on August 14, 2026 at 9:00 AM ET to review these results and anticipates no change to previously disclosed preliminary sales figures.
Details
News Market Reaction – ICCC
On Aug 7, the first trading day after this news, ICCC closed 0.18% below the previous close. Our momentum scanner recorded 3 alerts in the available session data.
Data tracked by StockTitan Argus for the Aug 7 session.
Key Figures
- Quarter End
- June 30, 2026
- Quarterly reporting period
- Results Release Date
- August 13, 2026
- After market close
- Conference Call
- August 14, 2026 at 9:00 AM ET
- Review of unaudited financial results
Previous Earnings date Reports
-
Scheduled March-quarter results, conference call, and Form 10-Q filing
-
Scheduled fourth-quarter and full-year results with preliminary sales unchanged
-
Scheduled September-quarter results, conference call, and Form 10-Q filing
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
unaudited financial
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026.
The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).
The live webcast can be accessed at: https://app.webinar.net/EQx8PqBGe36
The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/
A teleconference replay of the conference call will be available through August 21, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #8659150.
A webcast replay will also be available at: https://app.webinar.net/EQx8PqBGe36
The Company anticipates no change to the preliminary sales results for the quarter ended June 30, 2026 that were disclosed on July 9, 2026. The Company expects to file its Quarterly Report on Form 10-Q on August 13, 2026 after the market closes.
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.